Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
|Slideshows|September 5, 2019
Joint AAD, NPF phototherapy guidelines
Author(s)David Ozeri, M.D.
Listen
0:00 / 0:00
Discover key takeaways from the American Academy of Dermatology and National Psoriasis Foundation joint guidelines for the management and treatment of psoriasis with phototherapy published in the September issue of the Journal of American Academy of Dermatology.
Advertisement
References:
Elmets, Craig A., et al. Joint American Academy of DermatologyâNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775â804
Advertisement
Related to this article
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology Times Spot Test: September 27, 2026
5